Iggenix, Inc

Iggenix, Inc company information, Employees & Contact Information

Explore related pages

Related company profiles:

IgGenix is a clinical-stage, venture backed biotechnology company founded on breakthrough advances in Steve Quake’s laboratory at Stanford in collaboration with allergy clinician and researcher Kari Nadeau. We have exciting opportunities for enthusiastic, self-motivated, and highly organized individuals to join the growing team at IgGenix in South San Francisco, CA.

Company Details

Employees
12
Founded
-
Address
South San Francisco, Ca 94080, Us
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Milpitas.
HQ
South San Francisco, CA
Looking for a particular Iggenix, Inc employee's phone or email?

Iggenix, Inc Questions

News

IgGenix Announces Completion of Enrollment for Phase 1 Clinical Trial "ACCELERATE Peanut" with IGNX001 in Peanut Allergy - Yahoo Finance

IgGenix Announces Completion of Enrollment for Phase 1 Clinical Trial "ACCELERATE Peanut" with IGNX001 in Peanut Allergy Yahoo Finance

RNA sequencing uncovers more than 60 monoclonal antibodies linked to alpha-gal syndrome - Healio

RNA sequencing uncovers more than 60 monoclonal antibodies linked to alpha-gal syndrome Healio

Q&A: First patient dosed in IgGenix ACCELERATE Peanut phase 1 clinical trial - Healio

Q&A: First patient dosed in IgGenix ACCELERATE Peanut phase 1 clinical trial Healio

IgGenix Announces First Patient Dosed in Phase 1 Clinical Trial "ACCELERATE Peanut" Evaluating IGNX001 in Peanut Allergy - PR Newswire

IgGenix Announces First Patient Dosed in Phase 1 Clinical Trial "ACCELERATE Peanut" Evaluating IGNX001 in Peanut Allergy PR Newswire

IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy - Business Wire

IgGenix Announces First Close of $40M Series B Financing to Accelerate Lead Antibody Program in Peanut Allergy Business Wire

IgGenix: engineering antibodies to fight food allergies - Nature

IgGenix: engineering antibodies to fight food allergies Nature

IgGenix sprints to clinic with peanut allergy candidate and additional $40M - Endpoints News

IgGenix sprints to clinic with peanut allergy candidate and additional $40M Endpoints News

IgGenix Demonstrates Potential of IGNX001 as a Targeted Therapeutic for Peanut Allergy at the 2024 EAACI Annual Meeting Ahead of Clinical Trial Launch - PR Newswire

IgGenix Demonstrates Potential of IGNX001 as a Targeted Therapeutic for Peanut Allergy at the 2024 EAACI Annual Meeting Ahead of Clinical Trial Launch PR Newswire

IgGenix to Present Alpha-gal Syndrome Monoclonal Antibody Discovery at 2025 AAAAI / WAO Joint Congress - PR Newswire

IgGenix to Present Alpha-gal Syndrome Monoclonal Antibody Discovery at 2025 AAAAI / WAO Joint Congress PR Newswire

Top Iggenix, Inc Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant